Studies of Hirano Bodies in Living Cells

描述（由申请人提供）：阿尔茨海默病的特点是深度进行性神经退行性变，不仅对患者，而且对家庭和照顾者都有毁灭性的影响。目前，还没有治愈阿尔茨海默病的方法，目前的治疗方法在所有患者的一个子集中提供了适度的进展延迟。为了开发新的治疗方法，确定可以调节毒性发展的途径至关重要。对遗传遗传性神经退行性疾病家族、阿尔茨海默病小鼠模型和细胞培养模型的研究表明，淀粉样蛋白肽（淀粉样蛋白前体蛋白的来源）和微管结合蛋白tau参与导致认知功能丧失的途径。平野体是一种富含肌动蛋白的结构，在包括阿尔茨海默病在内的许多疾病中，平野体在大脑中出现的数量越来越多。平野体的生理功能尚不清楚。然而，众所周知平野小体在淀粉样蛋白前体和tau蛋白的COOH末端区域积累。因此，平野体可能影响阿尔茨海默病的进展。我们最近开发了细胞培养模型和转基因小鼠模型来研究平野体。该项目的长期目标是了解平野体对疾病进展的影响。这项提议的目的是测试平野体促进或保护阿尔茨海默病病理发展的假设。为了实现这一目标，平野体小鼠模型将与具有淀粉样前体蛋白或tau诱导的神经变性症状的转基因阿尔茨海默氏症模型小鼠杂交。结果将通过免疫组织化学、电生理学和行为研究来评估平野小体对体内神经病理学发展和认知能力下降的影响。这些研究将严格检验平野体可以调节阿尔茨海默病神经毒性的假设。此外，这些研究将揭示平野体是否会影响淀粉样前体蛋白和/或tau蛋白引发的毒性。如果结果表明平野小体可以调节这种疾病的进展，那么参与平野小体形成或降解的途径将被确定为治疗阿尔茨海默病的药物开发的新靶点。

DESCRIPTION (provided by applicant): Alzheimer's disease is characterized by profound progressive neurodegeneration that has devastating effects not only on patients but also on families and caregivers. At present, there is no cure for Alzheimer's disease, and current treatments provide modest delay in progression in a subset of all patients. It is essential to identify pathways that can modulate the development of toxicity in order to develop new treatments. Studies of families with genetically inherited neurodegenerative disease, mouse models of Alzheimer's disease, and cell culture models implicate the amyloid beta peptide, the amyloid precursor protein from which amyloid beta is derived, and the microtubule binding protein tau in pathways that lead to loss of cognitive function. Hirano bodies are actin-rich structures that appear in the brain in increased numbers in association with many conditions including Alzheimer's disease. The physiological function of Hirano bodies is not known. However, it is known that Hirano bodies accumulate COOH terminal regions of the amyloid precursor protein and also tau. Therefore, Hirano bodies could influence the progression of Alzheimer's disease. We have recently developed cell culture models and a transgenic mouse model for studies of Hirano bodies. The long term goal of this project is to understand the impact of Hirano bodies on the progression of disease. The goal of this proposal is to test the hypothesis that Hirano bodies either promote or protect from development of pathology in Alzheimer's disease. To achieve this objective, a mouse model of Hirano bodies will be crossed with transgenic Alzheimer's model mice that have symptoms of neurodegeneration induced either by amyloid precursor protein or tau. The outcomes will be assessed using immunohistochemistry, electrophysiology, and behavioral studies to assess the effect of Hirano bodies on development of neuropathology and cognitive decline in vivo. These studies will critically test the hypothesis that Hirano bodies can modulate neurotoxicity in Alzheimer's disease. In addition, the studies will reveal whether Hirano bodies can affect toxicity initiated by pathways involving amyloid precursor protein and/or tau. If the results show that Hirano bodies can modulate the progression of this disease, then pathways involved in formation or degradation of Hirano bodies would be identified as novel targets for drug development to treat Alzheimer's disease.